Relief Therapeutics Holding AG
🇨🇭XSWX.RLFSwitzerlandHealthcare
PriceCHF 3.00+0.11 (+3.81%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 8
- Medium: 1
- Low: 0
Volume: a spike above the 20-day average
Days inventory outstanding: a sudden spike above its trailing quarter average
Days payables outstanding: a sudden spike above its trailing quarter average
Operating cycle: a sudden spike above its trailing quarter average
Cash conversion cycle: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0100191136
- CUSIP
- Not reported
Company
- Employees
- 28
- Headquarters
- Geneva, Switzerland
Market
- Shares outstanding
- 12.6M
- Market cap
- CHF 37.73M
Highlights
- Market cap
- CHF 37.73M
- EPS LTM
- -CHF 7.29
- P/E LTM
- -0.41calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 19.28%calculatedCalculated by Finzer, not reported by the data provider.
Fundamentals (LTM)
- Revenue
- CHF 5.86M-10.68%down year on year
- Net income
- -CHF 80.79M-73.64%down year on year
- Gross margin
- -213.56%-68.1%down year on year
- Free cash flow
- -CHF 20.62M+37.19%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Relief Therapeutics Holding AG is a company in the healthcare sector, listed on SIX Swiss Exchange (Switzerland) under the ticker RLF. Its market capitalisation is CHF 37.73M, from 12.6M shares outstanding, as of . Across the 55 trading sessions to the shares traded between CHF 2.50 and CHF 4.49, and the last close of CHF 3.00 sits 25% of the way up that range. The company is headquartered in Geneva, Switzerland, and employs about 28 people.
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis. In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria. The company operates in Switzerland, Europe, North America, and internationally. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.